Nuwellis CEO outlines growth strategy focusing on pediatric market expansion and improved margins.

Nuwellis, Inc. announced a leadership change with Mike McCormick becoming CEO, emphasizing continued revenue growth and margin improvement. The company reported a 26% revenue increase in Q1 2026 and aims to expand its pediatric Aquadex therapy to smaller children while integrating new kidney monitoring technology from its recent acquisition. Nuwellis plans to maintain operational efficiency and capital discipline to support sustainable growth in critical care and pediatric markets.